Literature DB >> 19416642

EP(3) prostanoid receptor isoforms utilize distinct mechanisms to regulate ERK 1/2 activation.

Davelene D Israel1, John W Regan.   

Abstract

Prostaglandin-E(2) (PGE(2)) is a hormone derived from the metabolism of arachidonic acid whose functions include regulation of platelet aggregation, fever and smooth muscle contraction/relaxation. PGE(2) mediates its physiological and pathophysiological effects through its binding to four G-protein coupled receptor subtypes, named EP(1), EP(2), EP(3) and EP(4). The EP(3) prostanoid receptor is unique in that it has multiple isoforms generated by alternative mRNA splicing. These splice variants display differences in tissue expression, constitutive activity and regulation of signaling molecules. To date there are few reports identifying differential activities of EP(3) receptor isoforms and their effects on gene regulation. We generated HEK cell lines expressing the human EP(3-Ia), EP(3-II) or EP(3-III) isoforms. Using immunoblot analysis we found that nM concentrations of PGE(2) strongly stimulated the phosphorylation of ERK 1/2 by the EP(3-II) and EP(3-III) isoforms; whereas, ERK 1/2 phosphorylation by the EP(3-Ia) isoform was minimal and only occurred at muM concentrations of PGE(2). Furthermore, the mechanisms of the PGE(2) mediated phosphorylation of ERK 1/2 by the EP(3-II) and EP(3-III) isoforms were different. Thus, PGE(2) stimulation of ERK 1/2 phosphorylation by the EP(3-III) isoform involves activation of a Galpha(i)/PI3K/PKC/Src and EGFR-dependent pathway; while for the EP(3-II) isoform it involves activation of a Galpha(i)/Src and EGFR-dependent pathway. These differences result in unique differences in the regulation of reporter plasmid activity for the downstream effectors ELK1 and AP-1 by the EP(3-II) and EP(3-III) prostanoid receptor isoforms.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19416642      PMCID: PMC2679851          DOI: 10.1016/j.bbalip.2009.01.021

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  36 in total

1.  The duration, magnitude and compartmentalization of ERK MAP kinase activity: mechanisms for providing signaling specificity.

Authors:  Miki Ebisuya; Kunio Kondoh; Eisuke Nishida
Journal:  J Cell Sci       Date:  2005-07-15       Impact factor: 5.285

2.  Activated MEK stimulates expression of AP-1 components independently of phosphatidylinositol 3-kinase (PI3-kinase) but requires a PI3-kinase signal To stimulate DNA synthesis.

Authors:  I Treinies; H F Paterson; S Hooper; R Wilson; C J Marshall
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

3.  Fra-2-positive autoregulatory loop triggered by mitogen-activated protein kinase (MAPK) and Fra-2 phosphorylation sites by MAPK.

Authors:  M Murakami; M Ui; H Iba
Journal:  Cell Growth Differ       Date:  1999-05

4.  Constitutive activity of human prostaglandin E receptor EP3 isoforms.

Authors:  J Jin; G F Mao; B Ashby
Journal:  Br J Pharmacol       Date:  1997-05       Impact factor: 8.739

5.  Growth regulation of primary human keratinocytes by prostaglandin E receptor EP2 and EP3 subtypes.

Authors:  R L Konger; R Malaviya; A P Pentland
Journal:  Biochim Biophys Acta       Date:  1998-02-04

6.  Regulation of expression of matrix metalloproteinase-9 in early human T cells of the HSB.2 cultured line by the EP3 subtype of prostaglandin E2 receptor.

Authors:  L Zeng; S An; E J Goetzl
Journal:  J Biol Chem       Date:  1996-11-01       Impact factor: 5.157

7.  Prostaglandins induce proliferation of rat hepatocytes through a prostaglandin E2 receptor EP3 subtype.

Authors:  N Hashimoto; T Watanabe; Y Ikeda; H Yamada; S Taniguchi; H Mitsui; K Kurokawa
Journal:  Am J Physiol       Date:  1997-03

Review 8.  "Ins and outs" of seven-transmembrane receptor signalling to ERK.

Authors:  Tim D Werry; Patrick M Sexton; Arthur Christopoulos
Journal:  Trends Endocrinol Metab       Date:  2005 Jan-Feb       Impact factor: 12.015

9.  Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3.

Authors:  F Ushikubi; E Segi; Y Sugimoto; T Murata; T Matsuoka; T Kobayashi; H Hizaki; K Tuboi; M Katsuyama; A Ichikawa; T Tanaka; N Yoshida; S Narumiya
Journal:  Nature       Date:  1998-09-17       Impact factor: 49.962

10.  Activation of mitogen-activated protein kinase by the human prostaglandin EP3A receptor.

Authors:  T H Burkey; J W Regan
Journal:  Biochem Biophys Res Commun       Date:  1995-06-06       Impact factor: 3.575

View more
  11 in total

1.  Prostaglandin E2 receptor EP3 regulates both adipogenesis and lipolysis in mouse white adipose tissue.

Authors:  Hu Xu; Jia-Lin Fu; Yi-Fei Miao; Chun-Jiong Wang; Qi-Fei Han; Sha Li; Shi-Zheng Huang; Sheng-Nan Du; Yu-Xiang Qiu; Ji-Chun Yang; Jan-Åke Gustafsson; Richard M Breyer; Feng Zheng; Nan-Ping Wang; Xiao-Yan Zhang; You-Fei Guan
Journal:  J Mol Cell Biol       Date:  2016-07-19       Impact factor: 6.216

Review 2.  Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.

Authors:  Jocelyn Reader; Dawn Holt; Amy Fulton
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

3.  Genetic deletion of the prostaglandin E2 E prostanoid receptor subtype 3 improves anatomical and functional outcomes after intracerebral hemorrhage.

Authors:  Jenna L Leclerc; Andrew S Lampert; Matthew A Diller; Sylvain Doré
Journal:  Eur J Neurosci       Date:  2015-05       Impact factor: 3.386

Review 4.  Function of alternative splicing.

Authors:  Olga Kelemen; Paolo Convertini; Zhaiyi Zhang; Yuan Wen; Manli Shen; Marina Falaleeva; Stefan Stamm
Journal:  Gene       Date:  2012-08-15       Impact factor: 3.688

5.  Activation of PGE2/EP2 and PGE2/EP4 signaling pathways positively regulate the level of PD-1 in infiltrating CD8+ T cells in patients with lung cancer.

Authors:  Jinhong Wang; Li Zhang; Dong Kang; Deguang Yang; Ying Tang
Journal:  Oncol Lett       Date:  2017-10-26       Impact factor: 2.967

Review 6.  Therapeutic implications of the prostaglandin pathway in Alzheimer's disease.

Authors:  Eiron Cudaback; Nikolas L Jorstad; Yue Yang; Thomas J Montine; C Dirk Keene
Journal:  Biochem Pharmacol       Date:  2014-01-13       Impact factor: 5.858

7.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

8.  EP3 receptor isoforms are differentially expressed in subpopulations of primate granulosa cells and couple to unique G-proteins.

Authors:  Soon Ok Kim; Brandy L Dozier; Julie A Kerry; Diane M Duffy
Journal:  Reproduction       Date:  2013-10-21       Impact factor: 3.906

9.  PGE2/EP3/SRC signaling induces EGFR nuclear translocation and growth through EGFR ligands release in lung adenocarcinoma cells.

Authors:  Lorenzo Bazzani; Sandra Donnini; Federica Finetti; Gerhard Christofori; Marina Ziche
Journal:  Oncotarget       Date:  2017-05-09

10.  The Prostaglandin EP3 Receptor Is an Independent Negative Prognostic Factor for Cervical Cancer Patients.

Authors:  Helene Heidegger; Sebastian Dietlmeier; Yao Ye; Christina Kuhn; Aurelia Vattai; Caroline Aberl; Udo Jeschke; Sven Mahner; Bernd Kost
Journal:  Int J Mol Sci       Date:  2017-07-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.